Erick Gamelin, Chief Development Officer of Acrivon Therapeutics, Inc., filed a statement of changes in beneficial ownership on November 19, 2026, disclosing a disposition of 416 shares of common stock on November 17, 2026.
Key Highlights
- Reporting person: Erick Gamelin, Chief Development Officer of Acrivon Therapeutics, Inc.
- Transaction date: November 17, 2026, with the filing submitted on November 19, 2026.
- Shares disposed: 416 shares of common stock sold (transaction code S) to satisfy mandatory tax withholding upon vesting of restricted stock units.
- Weighted average price: $1.45 per share, reflecting a broker's sale of 4,070 shares across a group of employees on a pro rata basis.
- Remaining ownership: Gamelin directly holds 52,176 shares of common stock following the transaction.
- Issuer: Acrivon Therapeutics, Inc., traded on NASDAQ:ACRV.
Gamelin's RSU Vesting Transaction at Acrivon Therapeutics
According to the filing, Erick Gamelin disposed of 416 shares of Acrivon Therapeutics common stock on November 17, 2026. The filing states that these shares were "sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units," meaning the sale was not a discretionary market transaction initiated by Gamelin.
The filing notes that the $1.45 price per share reported represents a weighted average, as a broker sold a total of 4,070 shares on that date on behalf of a group of Acrivon Therapeutics employees to cover their collective withholding tax liabilities. The proceeds from those sales were then allocated to each participating employee, including Gamelin, on a pro rata basis. Following this disposition, Gamelin directly held 52,176 shares of Acrivon Therapeutics common stock, according to the filing.
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Gamelin serves as Chief Development Officer, a role that designates him as an officer subject to Section 16(a) reporting requirements under the Securities Exchange Act of 1934. The filing was signed by Adam D. Levy as attorney-in-fact on November 19, 2026, the same date it was submitted to the SEC.
What Was Disclosed
The filing disclosed a disposition of 416 shares of Acrivon Therapeutics common stock by Chief Development Officer Erick Gamelin at a weighted average price of $1.45 per share on November 17, 2026, executed automatically for tax withholding purposes upon RSU vesting, leaving him with 52,176 shares held directly.


Please wait processing your request...